NCT01770483

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Services Institute of Medical Sciences, Pakistan · Other Government
• Sex: All
• Age: 35 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response by more than 80%.Considering that the study is being conducted in a third world country like Pakistan, the standard treatment of hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in efficacy to peginterferon and also cost effective.

Detailed description

After taking proper informed consent from patients, patients who fulfill the research criteria are randomized into 2 groups (control/study). Patients in both groups will be treated with conventional interferon alfa and Ribavirin.Those in study group will be given tab nitazoxanide 500mg twice daily in addition to conventional treatment. The patients will be followed up at regular intervals: 0,4,12,24,48 week.At each visit Hepatitis C Virus(PCR)RNA, Liver function tests, complete blood count will be done.

Conditions

• Hepatitis C, Chronic
• DIABETES MELLITUS Type 2

Interventions

Type	Name	Description
DRUG	nitazoxanide	nitazoxanide 500mg twice daily
DRUG	conventional interferon alfa	Inj interferon 3 Million International Units thrice weekly
DRUG	Ribavirin	ribazole

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2013-01-17
• Last updated: 2013-09-20
• Results posted: 2013-04-17

Locations

1 site across 1 country: Pakistan